Skip to main content
. 2017 Mar 22;8(19):31815–31829. doi: 10.18632/oncotarget.16463

Figure 5. Combined effect of USP7 inhibitors and PARP inhibitors in the 22Rv1 cells.

Figure 5

(A) and (B) Top: Surviving fractions of 22Rv1 cells treated, in presence or absence of P5091 (2.5 μM), with olaparib at th indicated doses for 144 h are shown. DHT (10 nM) was added as indicated (−/+). Bottom: Drugs sensitivity to olaparib in presence or absence of P5091 (2.5 μM) was determined by a modified 3-(4,5-dimethylthiazole-2-yl)-2-5-diphenyltetrazolium bromide assay, CellTiter 96 Aqueous One Solution assay (Promega), as 50% inhibitory concentration (IC50) values.